Tag Archives: Hartaj Singh

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and Incyte (INCY – Research Report) with bullish sentiments. Gilead Sciences (GILD) In a report released

Moderna (MRNA) Receives a Buy from Oppenheimer

Oppenheimer analyst Hartaj Singh assigned a Buy rating to Moderna (MRNA – Research Report) today and set a price target of $108.00. The company’s shares closed last Monday at $83.25. According to TipRanks.com, Singh is a 5-star analyst with an

aTyr Pharma (LIFE) Receives a Buy from Oppenheimer

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on aTyr Pharma (LIFE – Research Report), with a price target of $8.00. The company’s shares closed last Tuesday at $3.87. According to TipRanks.com, Singh is a

Oppenheimer Gives a Buy Rating to Cellectis SA (CLLS)

Oppenheimer analyst Hartaj Singh assigned a Buy rating to Cellectis SA (CLLS – Research Report) today and set a price target of $35.00. The company’s shares closed last Thursday at $14.58. According to TipRanks.com, Singh is a 5-star analyst with

Sarepta Therapeutics (SRPT) Receives a Hold from Oppenheimer

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today. The company’s shares closed last Wednesday at $122.57. According to TipRanks.com, Singh is a 5-star analyst with an average return of 8.6% and a

Strongbridge Biopharma (SBBP) Gets a Buy Rating from Oppenheimer

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Strongbridge Biopharma (SBBP – Research Report), with a price target of $6.00. The company’s shares closed last Wednesday at $2.83. According to TipRanks.com, Singh is a